Supporting great companies through moments of turbulence with calm, credible leadership.

I work with turnaround firms, boards, and investors to rebuild trust, refocus strategy, and restore momentum in Medtech, Diagnostic, and Life Science companies. I bring clinical and scientific fluency to high-stakes situations, collaborating closely with legal, finance, and turnaround specialists to align stakeholders and provide steady, credible leadership.

Schedule a First Call

Trusted By…

I collaborate with leadership teams across private and publicly traded Medtech companies, as well as venture firms, private equity investors, academic institutions, and federal agencies. Whether building, rebuilding, or repositioning, my work is grounded in trust, discretion, and a shared urgency to deliver results.

About ArgoPond

Our Mission

ArgoPond provides hands-on strategic and operational support to medtech companies navigating moments of growth, turbulence, or transition. We focus on driving clarity, action, and alignment when stakes are high and time is short.

Who We Support

Founded and led by John Younger, MD, ArgoPond engages with medtech companies across the full lifecycle—from the first capital raised to life as a publicly traded company. We work directly with executive teams, boards, and investors to solve challenges in strategy, execution, and recovery.

Our clients include early-stage innovators, growth-phase ventures, public companies, and institutional investors seeking experienced leadership and trusted guidance.

What We Offer

While there’s no end to how challenges might present themselves, our engagements most often focus on:

  • Early-stage commercialization strategy and preparation
  • Stabilization, restructuring, and turnaround
  • Fractional and interim executive leadership (e.g., CEO or other C-suite roles, Head of Medical Affairs)
  • Board and investor support and alignment during times of uncertainty or reduced confidence

What Clients Say

Experienced Start-Up Investor, Board Member, Exiting Founder

Amidst a real crisis, he was asked to step in first to right the ship and ultimately to restructure the company altogether.  If I ever again needed to find someone who can step in and manage a clinical stage MedTech in trouble he is the only person I would think of calling.

Principal, Early Stage Investment Firm

As a board observer, I have worked closely with John in his role as restructuring CEO.  He is very perceptive and readily understands nuanced issues. He is deft at managing competing interests, differing visions and building a consensus.

Research Cardiologist, International Clinical Trialist

During the pandemic, John chaired the Data and Safety Monitoring Board for two international randomized controlled trials for new COVID therapeutics on which I was the lead investigator. He was very knowledgeable and responsive, promptly available for urgent questions and always thoughtful, keeping the safety of participants in mind, while emphasizing data integrity and the practicalities of trial execution.

Senior Executive, Large Scale Commercial and Scientific Real Estate Developer

John was an invaluable consultant as we sought an edge in an increasingly competitive and efficient life science market. He provided immediate value due to his exceptional understanding of the life science start-up community in a context that’s accessible and valuable to real estate investors and developers. His data driven approach to market analysis – including supply/demand fundamentals, types of end users and their real estate needs far exceeding our prior experience.  He’s also exceptionally well-connected nationally and can help with essential introductions to life science leaders in every facet of the industry.

About John Younger, MD

John brings over two decades of experience as a founder, operator, and investor in medtech. He has launched and led venture-backed medtech start-ups, managed an early-stage life science investment fund, and most recently as served as interim CEO of a commercial stage private medtech company through its restructuring.

He was the first emergency physician to serve on any NIH advisory council and the first entrepreneur appointed to the National Advisory Council for the National Institute of General Medical Sciences (NIGMS). He has also provided expert testimony before the U.S. House of Representatives Committee on Small Business, offering recommendations on how federal policy might better support early-stage life science companies beyond the traditional SBIR grant mechanism.

Whether the goal is to build, fix, or pivot, ArgoPond engages with clarity, urgency, and integrity—always with the aim of driving durable value for patients, companies, and shareholders alike.